Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Arthritis, Juvenile RheumatoidCrohn Disease
Interventions
DRUG

somatropin [rDNA origin] for injection

Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.

Trial Locations (1)

43205

Columbus Children's Hospital, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Nationwide Children's Hospital

OTHER